XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2021
Stock-Based Compensation [Abstract]  
Stock-Based Compensation Note 3. Stock-based Compensation

The Company recognizes compensation expense for stock options in accordance with Financial Accounting Standards Board (“FASB”) ASC 718, “Stock Based Compensation”. The expense of the option is generally measured at fair value at the grant date with compensation expense recognized over the service period, which is typically the vesting period. For grants subject to a service condition, the Company utilizes the Black-Scholes option-pricing model to estimate the fair value of each option on the date of grant. The Black-Scholes model takes into consideration the exercise price and expected life of the options, the current price of the underlying stock and its expected volatility, the expected dividends on the stock and the current risk-free interest rate for the expected life of the option. The Company’s estimate of the fair value of a stock option is based on expectations derived from historical experience and may not necessarily equate to its market value when fully vested. In accordance with ASC 718, the Company estimates the number of options for which the requisite service is expected to be rendered. At September 30, 2021, the Company had four active stock-based compensation plans.

The Company granted 100,000 stock options with a vesting period of four years during the nine month period ended September 30, 2021. The weighted average grant-date fair value was $8.51. The Company granted 300,000 stock options with a vesting period of four years during the nine month period ended September 30, 2020. The weighted average grant-date fair value was $3.02. There were 657,500 common stock options exercised in the nine month period ended September 30, 2021. There were 74,000 common stock options exercised in the nine month period ended September 30, 2020.

A summary of the Company’s stock options is presented below.

Weighted average

remaining

Weighted average

contractual

Aggregate

Options

exercise price

term (years)

intrinsic value

Outstanding at January 1, 2021

1,161,604 

$

7.62 

4.75 

$

7,001,843 

Granted

100,000 

18.81 

9.37 

664,000 

Exercised

(657,500)

7.51 

10,465,250 

Expired

Forfeited

Outstanding at September 30, 2021

604,104 

$

9.60 

6.81 

$

9,574,056 

Exercisable at September 30, 2021

246,552 

$

8.50 

4.03 

$

4,180,078 

The Company granted 313,697 restricted stock units (“RSUs”) in the first nine months of 2021 of which 261,073 have a vesting period of three years and 52,624 have a vesting period of one year. At issuance, the 313,697 RSUs granted in the first nine months of 2021 had a fair value of $18.81 per unit. In the first nine months of 2020, the Company granted 1,531,702 RSUs of which 1,387,602 have a vesting period of three years and 144,100 have a vesting period of one year. At issuance, the 1,531,702 RSUs granted in the first nine months of 2020 had a fair value of $6.87 per unit.

A summary of the status of the Company’s RSUs is presented below.

Weighted average

Average remaining

grant date

contractual

RSUs

fair value

term (years)

Outstanding at January 1, 2021

1,787,943 

$

7.49 

1.50 

Granted

313,697 

18.81 

2.03 

Vested

(672,533)

7.72 

Forfeited

(50,487)

8.73 

Outstanding at September 30, 2021

1,378,620 

$

9.91 

1.12 

As of September 30, 2021, there was a total of $9.3 million of unrecognized compensation cost related to unvested awards under share-based plans. This cost is expected to be recognized over a weighted average period of approximately 1.5 years. Related compensation expense for the nine months ended September 30, 2021 and 2020 was $6.5 million and $5.1 million, respectively. The total issuance date fair value of RSUs vested and options exercised during the nine months ended September 30, 2021 and 2020 was $7.6 million and $5.3 million, respectively. The total intrinsic value of the options exercised and RSUs vested in those respective periods was $25.3 million and $6.5 million, respectively.

For the periods ended September 30, 2021 and 2020, the Company estimated the fair value of each stock option grant on the date of grant using the Black-Scholes options pricing model with the following weighted average assumptions:

September 30,

2021

2020

Risk-free interest rate

1.19%

0.68%

Expected dividend yield

Expected volatility

45.61%

45.20%

Expected lives (years)

6.3 

6.3 

Expected volatility is based on the historical volatility of the Company’s stock and peer group comparisons over the expected life of the grant. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury strip rate in effect at the time of the grant. The life of the option is based on historical factors which include the contractual term, vesting period, exercise behavior and employee terminations. In accordance with ASC 718, Stock Based Compensation, stock based compensation expense for the period ended September 30, 2021 is based on awards that are ultimately expected to vest and has been reduced for estimated forfeitures. The Company estimated forfeitures using historical data based upon the groups identified by management.